Effectiveness of N-acetylcysteine in Treating Cocaine Dependent

Status Completed

Clinical Trial Summary

Recent findings have suggested that N-acetylcysteine (NAC) substantially reduces cocaine drug-seeking behavior in formerly cocaine dependent rats. The purpose of this study is to determine the safety, tolerability, and cue reactivity effects of NAC in cocaine dependent individuals and non-dependent healthy controls.

Clinical Trial Description

Recent findings have suggested that N-acetylcysteine (NAC) substantially reduces cocaine-primed drug-seeking behavior in formerly cocaine dependent rats. The purpose of this study is to determine the safety, tolerability, and cue reactivity effects of NAC in cocaine dependent individuals and non-dependent healthy controls.

Participants in this study will include 20 non-treatment seeking cocaine dependent individuals and 12 healthy, non-dependent controls. Participants will be recruited via word-of-mouth and advertisements. Cocaine dependent participants will undergo two 3-day hospital stays. Healthy controls will be followed throughout the study on an outpatient basis. All participants will be randomly assigned to receive either 600 mg of NAC or placebo. Medication or placebo will be administered twice each day. Participants will be evaluated for side effects throughout the study. After administration of the final dose of medication or placebo, participants will undergo cue reactivity testing. This will include a standardized protocol of slides demonstrating cocaine acquisition, use of cocaine, and cocaine-related paraphernalia. Before, during, and after cue reactivity procedures, standardized behavioral and cognitive scales will be used to assess cocaine craving, cocaine seeking, and subjective effects of the cocaine "high." The following week participants will be crossed over so that they will receive the other treatment. All study procedures will be performed a second time. Participants will be contacted during Week 3 in order to determine if any residual side effects or adverse events occurred from the medication and treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Cocaine-Related Disorders

Clinical Trial Details

NCT number	NCT00136825
Study type	Interventional
Source	National Institute on Drug Abuse (NIDA)
Contact
Status	Completed
Phase	Phase 1
Start date	March 2003
Completion date	September 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01526538` - Improving Learning-based Treatment of Cocaine Dependence With Medication	Phase 2
Completed	`NCT00877435` - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial	N/A
Completed	`NCT00430690` - Acoustic Startle Reduction In Cocaine Dependence
Completed	`NCT00217997` - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals	N/A
Active, not recruiting	`NCT00094315` - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1	Phase 1
Terminated	`NCT00142883` - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3	N/A
Completed	`NCT00218348` - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo	Phase 2
Completed	`NCT00158132` - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2	Phase 2
Completed	`NCT00142844` - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1	Phase 2
Completed	`NCT00000294` - Effects of Carvedilol on Cocaine Use in Humans - 11	Phase 2
Completed	`NCT00015054` - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3	Phase 2
Completed	`NCT00000308` - Dextroamphetamine-Cocaine Behavioral Intervention - 5	Phase 2
Completed	`NCT00000306` - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3	Phase 2
Completed	`NCT00000280` - Glutaminergic Agents for Cocaine Abuse - 5	Phase 1
Completed	`NCT00000278` - Disulfiram for Cocaine-Alcohol Abuse - 3	Phase 2
Completed	`NCT00000314` - M-CPP and Fenfluramine in Cocaine Addicts - 3	Phase 2
Completed	`NCT00000281` - Pharmacotherapy for Schizophrenic Drug Users - 6	Phase 2
Completed	`NCT00000282` - Pemoline for Cocaine Abuse - 7	Phase 2
Completed	`NCT00000188` - Selegiline in Treatment of Cocaine Dependence - 2	Phase 2
Completed	`NCT00000277` - Mazindol for Cocaine Abuse - 2	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms